Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%

Reuters

5 hours ago

Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%

Incannex Healthcare Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2612453420"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612453420\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612453420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 07:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612453420","market":"us","top_or_hot":-1,"title":"Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-19 07:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL31jhZr:1","article_id":"2612453420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612453420","pubTimestamp":1771457761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incannex Healthcare Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IXHL":"INCANNEX HEALTHCARE LTD"},"translate_title":"Incannex重点介绍2期RePOSA数据，显示IHL-42X可将OSA AHI降低高达83%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":0.9},"content_text":"Incannex Highlights Phase 2 RePOSA Data Showing IHL-42X Cuts OSA AHI by Up to 83%\n    \n\nIncannex Healthcare Inc. said it is continuing to build the clinical and patient-reported evidence base for its IHL-42X program in obstructive sleep apnea, citing full Phase 2 RePOSA data and exit-interview analyses that have already been presented. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index versus placebo, with maximum reductions of up to 83% in the high-dose arm, and that the treatment was well tolerated across both dose cohorts.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602181835NEWSFILECNPR____20260218_284430_1) on February 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}